158 related articles for article (PubMed ID: 36935008)
1. TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy.
Song T; Lv S; Ma X; Zhao X; Fan L; Zou Q; Li N; Yan Y; Zhang W; Sun L
J Biol Chem; 2023 May; 299(5):104621. PubMed ID: 36935008
[TBL] [Abstract][Full Text] [Related]
2. TFE3-SLC36A1 axis promotes resistance to glucose starvation in kidney cancer cells.
Lv S; Zhang Z; Li Z; Ke Q; Ma X; Li N; Zhao X; Zou Q; Sun L; Song T
J Biol Chem; 2024 May; 300(5):107270. PubMed ID: 38599381
[TBL] [Abstract][Full Text] [Related]
3. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
[TBL] [Abstract][Full Text] [Related]
4. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.
Kauffman EC; Ricketts CJ; Rais-Bahrami S; Yang Y; Merino MJ; Bottaro DP; Srinivasan R; Linehan WM
Nat Rev Urol; 2014 Aug; 11(8):465-75. PubMed ID: 25048860
[TBL] [Abstract][Full Text] [Related]
6. Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma.
Fang R; Wang X; Xia Q; Zhao M; Zhang H; Wang X; Ye S; Cheng K; Liang Y; Cheng Y; Gu Y; Rao Q
Oncogene; 2021 May; 40(18):3303-3317. PubMed ID: 33846569
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the dimerization mechanism of human transcription factor E3.
Yang G; Li P; Liu Z; Wu S; Zhuang C; Qiao H; Zheng L; Fang P; Lei C; Wang J
Biochem Biophys Res Commun; 2021 Sep; 569():41-46. PubMed ID: 34225079
[TBL] [Abstract][Full Text] [Related]
9. AKT inhibition-mediated dephosphorylation of TFE3 promotes overactive autophagy independent of MTORC1 in cadmium-exposed bone mesenchymal stem cells.
Pi H; Li M; Zou L; Yang M; Deng P; Fan T; Liu M; Tian L; Tu M; Xie J; Chen M; Li H; Xi Y; Zhang L; He M; Lu Y; Chen C; Zhang T; Wang Z; Yu Z; Gao F; Zhou Z
Autophagy; 2019 Apr; 15(4):565-582. PubMed ID: 30324847
[TBL] [Abstract][Full Text] [Related]
10. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
Guo X; Li R; Bai Q; Jiang S; Wang H
J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
[TBL] [Abstract][Full Text] [Related]
11. TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway.
Fang Y; Bao W; Rao Q; Wang X; Xia Q; Shen Q; Zhou X; Yao B
Mol Med Rep; 2017 Sep; 16(3):2721-2725. PubMed ID: 28713889
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
13. Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE).
Hirobe M; Masumori N; Tanaka T; Kitamura H; Tsukamoto T
Cancer Biol Ther; 2013 Jun; 14(6):502-10. PubMed ID: 23760492
[TBL] [Abstract][Full Text] [Related]
14. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
[TBL] [Abstract][Full Text] [Related]
15. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
[TBL] [Abstract][Full Text] [Related]
17. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting MT2-TFE3-dependent autophagy enhances melatonin-induced apoptosis in tongue squamous cell carcinoma.
Fan T; Pi H; Li M; Ren Z; He Z; Zhu F; Tian L; Tu M; Xie J; Liu M; Li Y; Tan M; Li G; Qing W; Reiter RJ; Yu Z; Wu H; Zhou Z
J Pineal Res; 2018 Mar; 64(2):. PubMed ID: 29149494
[TBL] [Abstract][Full Text] [Related]
19. Molecular heterogeneity of TFE3 activation in renal cell carcinomas.
Macher-Goeppinger S; Roth W; Wagener N; Hohenfellner M; Penzel R; Haferkamp A; Schirmacher P; Aulmann S
Mod Pathol; 2012 Feb; 25(2):308-15. PubMed ID: 22037260
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
Damayanti NP; Budka JA; Khella HWZ; Ferris MW; Ku SY; Kauffman E; Wood AC; Ahmed K; Chintala VN; Adelaiye-Ogala R; Elbanna M; Orillion A; Chintala S; Kao C; Linehan WM; Yousef GM; Hollenhorst PC; Pili R
Clin Cancer Res; 2018 Dec; 24(23):5977-5989. PubMed ID: 30061365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
